Optimal management of metastatic renal cell carcinoma: An algorithm for treatment

BJU International

Volumn 104, Issue 1, 2009, Pages 10-18

  Bellmunt, Joaquim ^a   Flodgren, Per ^b   Roigas, Jan ^c   Oudard, Stéphane ^d  

^a HOSPITAL DEL MAR   (Spain)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c VIVANTES KLINIKUM AM URBAN   (Germany)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Renal cell carcinoma; Sunitinib; Targeted therapy; Treatment algorithm

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BEVACIZUMAB; INTERLEUKIN 2; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; ALGORITHM; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; CLINICAL TRIAL; COMORBIDITY; DESQUAMATION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; METASTASIS; NAUSEA AND VOMITING; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; SHORT SURVEY; STOMATITIS;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INDOLES; INTERFERON-GAMMA; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TREATMENT OUTCOME;

EID: 67650506761     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08563.x     Document Type: Short Survey

References (63)

1. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 356 : 115 24
2. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 356 : 2271 81
3. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 356 : 125 34
4. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007 370 : 2103 11
5. Pfizer Inc. SUTENT, Summary of Product Characteristics, January 2008
6. Bayer Heathcare AG. Nexavar, Summary of Product Characteristics. 2007
7. Wyeth Pharmaceuticals I. Torisel Summary of Product Characteristics. 2007
8. Ravaud A. Key considerations in patient selection for the use of targeted therapy in metastatic renal cell carcinoma. Eur J Cancer Suppl 2007 5 : 20 7
9. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002 20 : 289 96
10. Motzer RJ, Figlin RA, Hutson TE et al. Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. Oral presentation at the American Society of Clinical Oncology Annual Meeting, Chicago, USA. 1-5 June 2007 (Abstract 5024)
11. Motzer RJ, Michaelson MD, Hutson TE. Sunitinib versus interferon (IFN) -alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors. Eur J Cancer Suppl 2007 5 : 301 (Abstract P4509)
12. Bukowski R, Szczylik C, Stadler W, Simantov R, Shan M. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 2007 25 : 240s (Abstract 5023)
13. Rini BI, Halabi S, Rosenberg JE et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Oral presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, California, USA, 14-16 February 2008
14. Dutcher JP, Szczylik C, Tannir N et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 2007 25 : 243s (Abstract 5033)
15. Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN) -alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008 26 : 256s
16. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006 24 : 16 24 (Pubitemid 46630489)
17. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006 295 : 2516 24
18. Motzer RJ, Michaelson MD, Rosenberg J et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007 178 : 1883 7
19. Motzer R, Rini BI, Michaelson MD et al. Sunitinib malate (SU.8) shows antitumor activity in patients with metastatic renal cell carcinoma: updated results from phase II trials. Eur J Cancer 2005 1124 : 6
20. Hariharan S, Szczylik C, Porta C et al. Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial. J Clin Oncol 2008 26 : 273s (Abstract 5094)
21. Medioni J, Cojocarasu O, Belcaceres J-L et al. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 2007 18 : 1282 3
22. Porta C, Szczylik C, Bracarda S et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. J Clin Oncol 2008 26 : 278s (Abstract 5114)
23. Oudard S, Szczylik C, Porta C et al. Expanded-access study of sunitinib in metastatic renal cell carcinoma: safety and efficacy results with subpopulation analysis. Poster presented at 19th International Congress on Anti Cancer Treatment, Paris, France. 5-8 February 2008
24. Bhojani N, Jeldres C, Patard JJ et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008 53 : 917 30
25. Negrier S, Ravaud A. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer Suppl 2007 5 : 12 9
26. Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S. Randomized phase II trial of first line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007 25 : 241s (Abstract 5025)
27. Ryan CW, Bukowski RM, Figlin R et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: long-term outcomes in first-line patients (pts). J Clin Oncol 2007 25 : 258s (Abstract 5096)
28. Henderson CA, Bukowski RM, Stadler WM et al. Sorafenib therapy in the management of advanced renal cell carcinoma with brain metastases: results from the ARCCS expanded access program. Eur Urol Suppl 2008 7 : 245
29. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004 22 : 909 18
30. Melichar B, Koralewski P, Pluzanska A et al. First-line bevacizumab improves progression-free survival with lower doses of interferon[alpha]2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN). Poster presented at 16th European Cancer Conference (ECCO), Barcelona, Spain. 23-27 September 2007
31. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 349 : 427 34
32. Bukowski RM, Kabbinavar FF, Figlin RA et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007 25 : 4536 41
33. Ljungberg B, Hanbury D, Kuczyk M. Renal cell carcinoma guideline. Eur Urol 2007 51 : 1502 10
34. Ravaud A. Targeted therapy in metastatic renal cell carcinoma: efficacy, adverse-event management and key considerations. Eur J Cancer Suppl 2007 5 : 1 3 (Pubitemid 350017069)
35. Bellmunt J. The oncologist's view: targeted therapies in advanced renal cell carcinoma. Euro Urol Suppl 2008 7 : 55 62
36. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008 358 : 95 7
37. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999 17 : 2530 40
38. Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007 110 : 543 50
39. Choueiri TK, Rini B, Garcia JA et al. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann Oncol 2007 18 : 249 55
40. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004 22 : 454 63
41. Negrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002 13 : 1460 8
42. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008 26 : 127 31
43. Cheville JC, Lohse CM, Zincke H et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003 27 : 612 24
44. Stadler W, Figlin R. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial. Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J Clin Oncol 2007 25 : 243s (Abstract 5036)
45. Golshayan AR, Choueiri TK, Elson P et al. Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy. J Clin Oncol 2007 25 : 246s (Abstract 5046)
46. Jac J, Giessinger S, Khan M et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 2007 25 : 261s
47. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995 13 : 688 96
48. McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005 23 : 133 41
49. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003 21 : 3127 32
50. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003 9 : 802 11
51. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005 11 : 3714 21
52. Escudier B, Koralewski P, Pluzanska A et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 2007 25 : 2s (Abstract 3)
53. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer V.1. 2009. Available at: http://www.nccn.org/ professionals/physician-gls/PDF/kidney.pdf. Accessed 30 March 2009
54. Bukowski RM. Future directions in targeted therapy for renal carcinoma. Oral presentation at the American Society of Clinical Oncology Annual Meeting, Chicago, USA. 1-5 June 2007 (Abstract 5023)
55. Knox J, Figlin RA, Stadler WM et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America. Safety and efficacy. J Clin Oncol 2007 25 : 237s (Abstract 5011)
56. Tamaskar I, Garcia JA, Elson P et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008 179 : 81 6
57. George D, Michaelson D, Rosenberg JE et al. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers. J Clin Oncol 2007 25 : 243s (Abstract 5035)
58. Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007 8 : 975 84
59. Rini B, Wilding G, Hudes G et al. Axitinib (AG013736; AG) in patients with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib. Eur J Cancer Suppl 2007 5 : 300 (Abstract 04507)
60. Hurwitz H, Dowlati A, Savage S et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in patients with solid tumors. J Clin Oncol 2005 23 : 195s (Abstract 3012)
61. Hutson TE, Davis ID, Machiels JP et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC). Interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 2007 25 : 242s (Abstract 5031)
62. Amato R, Misellati A, Khan M et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 2006 24 : 224s (Abstract 4530)
63. Escudier B, Ravaud A, Oudard S et al. Phase-3 randomised trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma. Oral presentation at the 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, September 2008 : 12 6 (Abstract 720)